Treatment For Pv: Moving Beyond Hydroxyurea

Moving Beyond Hydroxyurea for Polycythemia Vera

Targeted Oncology

Dr. John Mascarenhas, MD - PV Moving Beyond Hydroxyurea

MPN Advocacy and Education

Polycythemia vera: When to move from hydroxyurea to second-line therapy

PV-AIM: using machine learning to predict resistance to hydroxyurea therapy in patients with PV

VJHemOnc – Video Journal of Hematology & HemOnc

Challenges and options for patients with hydroxyurea-resistant PV

VJHemOnc – Video Journal of Hematology & HemOnc

How Do You Treat PV Patients That Fail Hydroxyurea (HU)?

PV: Clinical Use of Hydroxyurea

The current treatment algorithm for polycythemia vera

VJHemOnc – Video Journal of Hematology & HemOnc

Using Hydroxyurea in a Patient With Polycythemia Vera

Targeted Oncology

The Efficacy and Safety of Hydroxyurea Therapy Vs.Switching to Ruxolitinib in PV Patients

Can ruxolitinib replace hydroxyurea as a frontline therapy for PV?

SSBMT Webinar Series - How I Treat PV/ET beyond Hydroxyurea - 28 November 2020

SSBMT جمعية الخلايا الجذعية

Looking Beyond Hematocrit Control in Polycythemia Vera

Hydroxyurea Intolerance/Resistance in Polycythemia vera

Assessing Response to Hydroxyurea Treatment

Targeted Oncology

PV: Treatment With Ruxolitinib

Goals of Therapy in Polycythemia Vera

Managing Challenges with Traditional Treatments: Polycythemia Vera

Annenberg Center for Health Sciences

Practical Considerations of Polycythemia Vera Treatment

Case 2: A PV Patient with Intolerance to Hydroxyurea

Targeted Oncology